Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2025 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports Second Quarter 2025 Financial Results

– FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully...
August 04, 2025 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
July 31, 2025 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Report Second Quarter 2025 Financial Results

SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
July 03, 2025 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
June 12, 2025 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – ...